Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immuno-Targeted Agents and Low-Dose Chemotherapy in Ph- B-ALL
NCT07643103Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2026
- Primary completion
- May 2028
01
Overview
A Phase 2 trial of inotuzumab ozogamicin, venetoclax, blinatumomab, CD19-directed chimeric antigen receptor T cells in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
inotuzumab ozogamicinvenetoclaxblinatumomabCD19-directed chimeric antigen receptor T cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07643103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07643103.